Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2006-8-3
pubmed:abstractText
We previously reported that stable overexpression of protein kinase C alpha (PKCalpha) in hormone responsive T47D:A18 breast cancer cells produces a hormone-independent/tamoxifen (TAM)-resistant and 17beta-estradiol (E2)-inhibitory phenotype in vivo. Furthermore, overexpression of PKCalpha in T47D:A18 cells also results in cross-upregulation of PKCs beta and delta. In this study, we further characterized the contribution of PKC isozymes alpha, beta and delta to this complex phenotype. To determine whether downregulation of PKCalpha is sufficient to restore the hormone-dependent phenotype in T47D:A18/PKCalpha cells, PKCalpha was selectively knocked down using short hairpin RNA (shRNA). To determine the contribution of PKCbeta or delta to the hormone-independent/TAM-resistant and E2-inhibitory phenotype, stable T47D:A18/PKCbeta and T47D:A18/PKCdelta clones were established. Downregulation of PKCalpha by shRNA in T47D:A18/PKCalpha20 cells also resulted in reduced PKCbeta protein expression in vitro. Tumors established from a T47D:A18/PKCalpha/shRNA stable clone exhibit 50% reduction of PKCalpha protein without concomitant reduction in PKCbeta, and exhibit partial reversal of the TAM-resistant and E2-inhibitory phenotype in vivo. Furthermore, stable overexpression of neither PKCbeta nor PKCdelta in T47D:A18 cells are sufficient to produce hormone-independent growth in vitro or in vivo, nor TAM-resistant and E2-inhibited growth in vivo. Taken together, these results suggest that PKCalpha is required to impart the TAM-resistant and E2-inhibitory phenotype in vivo.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0143-3334
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1538-46
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16513679-Animals, pubmed-meshheading:16513679-Antineoplastic Agents, Hormonal, pubmed-meshheading:16513679-Drug Resistance, Neoplasm, pubmed-meshheading:16513679-Estradiol, pubmed-meshheading:16513679-Estrogen Receptor Modulators, pubmed-meshheading:16513679-Female, pubmed-meshheading:16513679-Humans, pubmed-meshheading:16513679-Mammary Neoplasms, Experimental, pubmed-meshheading:16513679-Mice, pubmed-meshheading:16513679-Mice, Inbred BALB C, pubmed-meshheading:16513679-Mice, Nude, pubmed-meshheading:16513679-Neoplasms, Hormone-Dependent, pubmed-meshheading:16513679-Phenotype, pubmed-meshheading:16513679-Protein Kinase C, pubmed-meshheading:16513679-Protein Kinase C-alpha, pubmed-meshheading:16513679-Protein Kinase C-delta, pubmed-meshheading:16513679-Tamoxifen, pubmed-meshheading:16513679-Tumor Cells, Cultured, pubmed-meshheading:16513679-Up-Regulation
pubmed:year
2006
pubmed:articleTitle
Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
pubmed:affiliation
Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, IL 60612, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural